Clinical Trial News and Research

RSS

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Academic Health Center scientists, physicians, and research centers have attracted 128 grants totaling nearly $35 million in federal stimulus money (as of Nov. 10) since the American Recovery and Reinvestment Act was approved in February 2009. This will result in a total economic impact of more than $105 million; according to the National Institutes of Health, $1 of research funding multiplies to more than $2 of goods and services in the economy.

11 Nov 2009

Sprycel holds hope for treating Src dependent ovarian cancer

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

11 Nov 2009

Financial results for third-quarter 2009 announced by PLC Systems

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three and nine month periods ended September 30, 2009.

11 Nov 2009

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.

10 Nov 2009

Mesenchymal stem cells may be the key to healing diabetic foot ulcers

Diabetic foot ulcers are the primary cause of hospital admissions for diabetics. Foot ulcers that heal improperly are at risk for infection, which can lead to amputation. According to the American Diabetes Association, one in four patients with diabetic foot ulcers will eventually require lower-limb amputation. Now science has found a way of mobilizing stem cells within the body to treat this health issue, which affects more than three million Americans annually.

10 Nov 2009

Low-fat diet improves mood and memory skills, says new study

After one year, a low-calorie, low-fat diet appears more beneficial to dieters' mood than a low-carbohydrate plan with the same number of calories, according to a report in the November 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

10 Nov 2009

FDA approved stem cell therapy restores limb function in rats with neck spinal cord injuries

The first human embryonic stem cell treatment approved by the FDA for human testing has been shown to restore limb function in rats with neck spinal cord injuries - a finding that could expand the clinical trial to include people with cervical damage.

10 Nov 2009

EpiCept announces third quarter 2009 financial results

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

10 Nov 2009

Harvest Technologies completes patient enrollment in its non-reconstructable Critical Limb Ischemia trial

Harvest Technologies Corp. announced today that the company sponsored 48-patient IDE clinical trial conducted at seven sites in the U.S. and one site in India using the company's Bone Marrow Aspiration Concentrate (BMAC) System to treat patients with non-reconstructable Critical Limb Ischemia (CLI) has completed enrollment. Mark D. Iafrati, M.D. Chief of Vascular Surgery at Tufts Medical Center in Boston, directed the study.

10 Nov 2009

FDA grants marketing approval for Wright Medical Group's CONSERVE Plus Total Hip Resurfacing System

Wright Medical Group, Inc., a global orthopaedic medical device company, announced today that the United States Food and Drug Administration (FDA) has given approval to the Company to market its original CONSERVE® Plus Total Hip Resurfacing System. Now available in the United States, this innovative total surface arthroplasty system provides surgeons and their patients a bone-conserving alternative to traditional total hip replacement.

9 Nov 2009

Clinipace acquires Worldwide Clinical Research, changes its name to Clinipace Worldwide

Clinipace, a global technology-driven clinical research organization (CRO), announced today that on October 26th, 2009 the company closed its acquisition of Worldwide Clinical Research, Inc. (WWCR), a Midwest-based CRO specializing in the management of clinical studies for biotechnology and pharmaceutical companies. With the acquisition, Clinipace has changed its name to Clinipace Worldwide.

9 Nov 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

CytRx reports financial results for the three months and nine months ended September 30, 2009

CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.

9 Nov 2009

Cardiome Pharma announces financial results for the three months ended September 30, 2009

Cardiome Pharma Corp. today reported financial results for the third quarter ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).

9 Nov 2009

GTx reports financial results for the third quarter of 2009

GTx, Inc. today reported financial results for the third quarter of 2009. The net loss for the third quarter and nine months ended September 30, 2009 was $12.8 million and $35.4 million, respectively, compared with a net loss of $11.9 million and $37.9 million for the same periods in 2008. At September 30, 2009 GTx had cash, cash equivalents and short-term investments of $55.5 million.

9 Nov 2009

Chinese SFDA approves China Medical Technologies' Leukemia BCR/ABL fusion gene detection FISH Probe

China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its Leukemia BCR/ABL fusion gene detection FISH Probe (the "Leukemia BCR/ABL FISH Probe") from the State Food and Drug Administration of China (the "SFDA").

9 Nov 2009

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company’s strategic alliance with GlaxoSmithKline.

9 Nov 2009

PAREXEL International forms an alliance with Mortara Instrument, enhances cardiac safety capabilities

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has enhanced its cardiac safety capabilities for early phase clinical development through an alliance with Mortara Instrument, Inc., which manufactures and distributes electrocardiogram (ECG) devices and related technology worldwide.

From Parexel 9 Nov 2009

Financial results for the third-quarter announced by Repros Therapeutics

Repros Therapeutics today announced financial results for the third quarter ended September 30, 2009.

9 Nov 2009

Clinical Trial News and Research

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Sprycel holds hope for treating Src dependent ovarian cancer

Financial results for third-quarter 2009 announced by PLC Systems

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Mesenchymal stem cells may be the key to healing diabetic foot ulcers

Low-fat diet improves mood and memory skills, says new study

FDA approved stem cell therapy restores limb function in rats with neck spinal cord injuries

EpiCept announces third quarter 2009 financial results

Harvest Technologies completes patient enrollment in its non-reconstructable Critical Limb Ischemia trial

FDA grants marketing approval for Wright Medical Group's CONSERVE Plus Total Hip Resurfacing System

Clinipace acquires Worldwide Clinical Research, changes its name to Clinipace Worldwide

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

CytRx reports financial results for the three months and nine months ended September 30, 2009

Cardiome Pharma announces financial results for the three months ended September 30, 2009

GTx reports financial results for the third quarter of 2009

Chinese SFDA approves China Medical Technologies' Leukemia BCR/ABL fusion gene detection FISH Probe

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

PAREXEL International forms an alliance with Mortara Instrument, enhances cardiac safety capabilities

Financial results for the third-quarter announced by Repros Therapeutics

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer